 The gross proceeds to Catalyst from this offering were approximately 30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst. All of the shares in the offering were sold by Catalyst. Catalyst anticipates using the net proceeds from this offering for general corporate purposes, which may include research and development activities in its complement program, clinical and manufacturing activities for marzeptacog alfa and dalcinonacog alfa, other research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. 